Compound ID | 1319
Class: Aminoacyl-tRNA synthetase inhibitor (tryptophanyl-tRNA synthetase [TrpS] inhibitor)
Spectrum of activity: | Gram-positive |
Details of activity: | Indolmycin is bacteriostatic and demonstrates good activity against MSSA (methicillin-susceptible Staphylococcus aureus), MRSA (methicillin-resistant S. aureus) and VISA (vancomycin-intermediate S. aureus), including strains resistant to mupirocin or fusidic acid. |
Institute where first reported: | Chas. Pfizer & Co., Inc., Groton, Connecticut |
Year first mentioned: | 1980 |
Highest developmental phase: | Preclinical |
Development status: | Active |
Chemical structure(s): | |||||||||||
|
|
External links: | |
PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/135417159 |
Guide to Pharmacology: | indolmycin |
Citations: |
|